MGMT expression and pituitary tumours: Relationship to tumour biology

Pituitary

Volumn 16, Issue 2, 2013, Pages 208-219

  McCormack, Ann ^a,b   Kaplan, Warren ^c   Gill, Anthony J ^a,d   Little, Nicholas ^e   Cook, Raymond ^e   Robinson, Bruce ^f   Clifton Bligh, Roderick ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Royal North Shore and North Shore Private Hospitals   (Australia)

^f University of Sydney   (Australia)

Author keywords

MGMT; Pituitary tumorigenesis; Pituitary tumour; Temozolomide

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; FEMALE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SET ENRICHMENT ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE GENE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84878761644     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0406-8     Document Type: Article

References (60)

1. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91(12):4769-4775
2. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377-382. doi: 10.1111/j.1365-2265.2009.03667.x
3. Melmed S (2011) Pathogenesis of pituitary tumors. Nat Rev Endocrinol 7(5):257-266. doi: 10.1038/nrendo.2011.40
4. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804-812
5. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S (2008) p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 105(45):17498-17503
6. Chesnokova V, Melmed S (2010) Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol 326(1-2):55-59. doi: 10.1016/j.mce.2010.02.012
7. Vandeva S, Tichomirowa MA, Zacharieva S, Daly AF, Beckers A (2010) Genetic factors in the development of pituitary adenomas. Endocr Dev 17:121-133. doi: 10.1159/000262534
8. Gueorguiev M, Grossman AB (2009) Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary 12(3):245-255. doi: 10.1007/s11102-008-0147-x
9. Dworakowska D, Grossman AB (2009) The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23(5):525-541
10. Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97-126
11. Vidal S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, Scheithauer BW (2002) Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior. Mod Pathol 15(11):1205-1212
12. Pan LX, Chen ZP, Liu YS, Zhao JH (2005) Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74(1):71-76
13. Qian ZR, Li CC, Yamasaki H, Mizusawa N, Yoshimoto K, Yamada S, Tashiro T, Horiguchi H, Wakatsuki S, Hirokawa M, Sano T (2002) Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol 15(12):1357-1365
14. Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65(4):536-543
15. McCabe CJ, Khaira JS, Boelaert K, Heaney AP, Tannahill LA, Hussain S, Mitchell R, Olliff J, Sheppard MC, Franklyn JA, Gittoes NJ (2003) Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) 58(2):141-150
16. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide, Report of two cases. J Neurosurg 105(4):621-626
17. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81-86
18. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65(4):552-553
19. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM (2009) Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol 160(1):115-119
20. Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64(4):E773-E774 (discussion E774)
21. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ (2009) Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71(2):226-233
22. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: a French Multicenter Experience. J Clin Endocrinol Metab 95(10):4592-4599. doi: 10.1210/jc.2010-0644
23. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML, Thorner MO, Laws ER Jr, Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280-E290. doi: 10.1210/jc.2010-0441
24. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M (2010) Salvage therapy with Temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843-851. doi: 10.1530/EJE-10-0629
25. McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41(10):1133-1148. doi: 10.1111/j.1365-2362.2011.02520.x
26. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R (2010) MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 13(4):367-379. doi: 10.1007/s11102-010-0249-0
27. Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E (2009) O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer 115(5):1070-1080
28. Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S (2009) High incidence of low O6-methylguanine DNA methyltransferase (MGMT) expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol 161(4):553-559
29. Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, Kovacs K, Horvath E, Lloyd RV (2011) MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 104(3):647-657. doi: 10.1007/s11060-011-0532-6
30. Salehi F, Scheithauer BW, Kovacs K, Horvath E, Syro LV, Sharma S, Manoranjan B, Cusimano M (2012) O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery 70(2):491-496. doi: 10.1227/NEU.0b013e318230ac63
31. Lloyd RV, Kovacs K, Young WF (2004) Pituitary tumors. WHO classification of tumours of the endocrine organs. IARC Press, Lyon
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550. doi: 10.1073/pnas.0506580102
33. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3):267-273. doi: 10.1038/ng1180
34. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Loze MT, Tang D, Cao L (2011) DAMP-mediated autophagy contributes to drug resistance. Autophagy 7(1):112-114
35. Mlynarczuk-Bialy I, Roeckmann H, Kuckelkorn U, Schmidt B, Umbreen S, Golab J, Ludwig A, Montag C, Wiebusch L, Hagemeier C, Schadendorf D, Kloetzel PM, Seifert U (2006) Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res 66(15):7598-7605. doi: 10.1158/0008-5472.CAN-05-2614
36. Srougi MC, Burridge K (2011) The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage. PLoS One 6(2):e17108. doi: 10.1371/journal.pone.0017108
37. Warmerdam DO, Kanaar R (2010) Dealing with DNA damage: relationships between checkpoint and repair pathways. Mutat Res 704(1-3):2-11. doi: 10.1016/j.mrrev.2009.12.001
38. Im JS, Jung BH, Kim SE, Lee KH, Lee JK (2010) Per3, a circadian gene, is required for Chk2 activation in human cells. FEBS Lett 584(23):4731-4734. doi: 10.1016/j.febslet.2010.11.003
39. Kaina B (2003) DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem Pharmacol 66(8):1547-1554. doi: S0006295203005100
40. Egly JM, Coin F (2011) A history of TFIIH: two decades of molecular biology on a pivotal transcription/repair factor. DNA Repair (Amst). doi: 10.1016/j.dnarep.2011.04.021
41. Cordin O, Banroques J, Tanner NK, Linder P (2006) The DEAD-box protein family of RNA helicases. Gene 367:17-37. doi: 10.1016/j.gene.2005.10.019
42. Kohler A, Hurt E (2010) Gene regulation by nucleoporins and links to cancer. Mol Cell 38(1):6-15. doi: 10.1016/j.molcel.2010.01.040
43. Pereira LA, Klejman MP, Timmers HT (2003) Roles for BTAF1 and Mot1p in dynamics of TATA-binding protein and regulation of RNA polymerase II transcription. Gene 315:1-13. doi: S0378111903007145
44. Yu Y, Feng YM (2010) The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. Cancer 116(22):5150-5160. doi: 10.1002/cncr.25461
45. Fumoto K, Hoogenraad CC, Kikuchi A (2006) GSK-3beta-regulated interaction of BICD with dynein is involved in microtubule anchorage at centrosome. EMBO J 25(24):5670-5682. doi: 10.1038/sj.emboj.7601459
46. Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K (2010) Low Immunohistochemical Expression of MGMT in ACTH Secreting Pituitary Tumors of Patients with Nelson Syndrome. Endocr Pathol 21(4):227-229. doi: 10.1007/s12022-010-9138-3
47. Mineura K, Watanabe K, Yanagisawa T, Kowada M (1996) Quantification of O6-methylguanine-DNA methyltransferase mRNA in human brain tumors. Biochim Biophys Acta 1289(1):105-109
48. Citron M, Graver M, Schoenhaus M, Chen S, Decker R, Kleynerman L, Kahn LB, White A, Fornace AJ Jr, Yarosh D (1992) Detection of messenger RNA from O6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues. J Natl Cancer Inst 84(5):337-340
49. Fornace AJ Jr, Papathanasiou MA, Hollander MC, Yarosh DB (1990) Expression of the O6-methylguanine-DNA methyltransferase gene MGMT in MER + and MER- human tumor cells. Cancer Res 50(24):7908-7911
50. Boldogh I, Ramana CV, Chen Z, Biswas T, Hazra TK, Grosch S, Grombacher T, Mitra S, Kaina B (1998) Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. Cancer Res 58(17):3950-3956
51. Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L, Stapleton G (2000) Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme. Eur J Cancer 36(13 Spec No):1640-1648. doi: S0959-8049(00)00175-1
52. Fontijn D, Adema AD, Bhakat KK, Pinedo HM, Peters GJ, Boven E (2007) O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells. Mol Cancer Ther 6(10):2807-2815
53. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF, Valerie K (2009) Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8(8):730-738
54. Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y, Siegal T (2007) Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res 67(18):8952-8959
55. Shimura T, Kakuda S, Ochiai Y, Nakagawa H, Kuwahara Y, Takai Y, Kobayashi J, Komatsu K, Fukumoto M (2010) Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3beta-mediated cyclin D1 overexpression. Oncogene 29(34):4826-4837. doi: 10.1038/onc.2010.238
56. Niture SK, Doneanu CE, Velu CS, Bailey NI, Srivenugopal KS (2005) Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem Biophys Res Commun 337(4):1176-1184. doi: 10.1016/j.bbrc.2005.09.177
57. Nouspikel T (2009) DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell Mol Life Sci 66(6):994-1009. doi: 10.1007/s00018-009-8737-y
58. Gommans WM, Haisma HJ, Rots MG (2005) Engineering zinc finger protein transcription factors: the therapeutic relevance of switching endogenous gene expression on or off at command. J Mol Biol 354(3):507-519. doi: 10.1016/j.jmb.2005.06.082
59. Witkiewicz-Kucharczyk A, Bal W (2006) Damage of zinc fingers in DNA repair proteins, a novel molecular mechanism in carcinogenesis. Toxicol Lett 162(1):29-42. doi: 10.1016/j.toxlet.2005.10.018
60. Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B (2010) MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 12(8):822-833. doi: 10.1093/neuonc/noq017